Vincere Biosciences Inc
Vincere Biosciences is a Cambridge-based company dedicated to developing disease-modifying therapies for age-related diseases, including Parkinson’s and Kidney disease. The company leverages advanced AI/ML tools and has a strong focus on mitochondrial health and rejuvenation, with a mission to translate scientific findings into innovative treatments and skin care solutions. Backed by top agencies and expert investors, Vincere aims to accelerate the development of its lead USP30 inhibitor program, with the first molecule entering human trials in 2026. The company is committed to open science, continuous learning, and collaboration with leading research institutions and industry partners.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Lead USP30 small-molecule inhibitor program
A preclinical small-molecule program targeting a mitochondrial de-ubiquitinating enzyme implicated in mitophagy dysregulation; advanced through discovery and optimization toward IND-enabling studies with planned progression to human trials.
Lead USP30 small-molecule inhibitor program
A preclinical small-molecule program targeting a mitochondrial de-ubiquitinating enzyme implicated in mitophagy dysregulation; advanced through discovery and optimization toward IND-enabling studies with planned progression to human trials.
Services
Application of a proprietary computational platform combining multi-omics simulation, network analysis, AI/ML, and virtual screening to identify targets, prioritize molecules, and support patient selection; offered via collaborations and research partnerships.
Application of a proprietary computational platform combining multi-omics simulation, network analysis, AI/ML, and virtual screening to identify targets, prioritize molecules, and support patient selection; offered via collaborations and research partnerships.
Expertise Areas
- Mitophagy-targeted therapeutics
- Parkinson's disease drug development
- Small-molecule inhibitor discovery
- Computational drug discovery and AI/ML
Key Technologies
- AI/ML-driven drug discovery
- Deep neural networks for patient stratification
- Multi-omics simulation
- Large-scale virtual screening
News & Updates
Beiersdorf is making a strategic investment in Vincere Biosciences to develop new anti-aging skin care solutions based on scientific findings on mitochondrial health and rejuvenation.
Vincere Biosciences successfully completed its Series A funding, including participation from strategic investors such as Beiersdorf AG, Draper Associates, Kastor Capital, Portal Innovations, and Daewoong Pharma. The funding will support preclinical development and pipeline expansion.
Vincere Biosciences participated in the 16th annual Michael J. Fox Foundation Parkinson’s Disease Therapeutics Conference in October 2024, sharing latest innovations in PD therapeutics.
Vincere Biosciences was featured at the Longevity Summit Dublin in June 2024, focusing on longevity research and rejuvenation biotechnology.
In September 2023, Vincere Biosciences received a Phase 1 SBIR grant from the National Institute of Neurological Disorders and Stroke to develop inhibitors of USP30.
In September 2023, Vincere Biosciences was recognized as a finalist for the 'Start Up of the Year' award by Biotech Week Boston for growth and innovation.
Beiersdorf is making a strategic investment in Vincere Biosciences to develop new anti-aging skin care solutions based on scientific findings on mitochondrial health and rejuvenation.
Vincere Biosciences successfully completed its Series A funding, including participation from strategic investors such as Beiersdorf AG, Draper Associates, Kastor Capital, Portal Innovations, and Daewoong Pharma. The funding will support preclinical development and pipeline expansion.
Vincere Biosciences participated in the 16th annual Michael J. Fox Foundation Parkinson’s Disease Therapeutics Conference in October 2024, sharing latest innovations in PD therapeutics.
Vincere Biosciences was featured at the Longevity Summit Dublin in June 2024, focusing on longevity research and rejuvenation biotechnology.
In September 2023, Vincere Biosciences received a Phase 1 SBIR grant from the National Institute of Neurological Disorders and Stroke to develop inhibitors of USP30.
In September 2023, Vincere Biosciences was recognized as a finalist for the 'Start Up of the Year' award by Biotech Week Boston for growth and innovation.